Order byBest matchMost fresh
What will happen to your genetic data after 23andMe sale?
After acquiring 23andMe, Regeneron Pharmaceuticals has said it will protect user data as it uses DNA data for drug development.
Timeline: 23andMe’s Journey From DNA Testing Pioneer to Bankruptcy Sale
What happened to 23andMe? Here's a look at its history from launch to bankruptcy and acquisition by Regeneron.
A drug developer is buying 23andMe - what does that mean for your DNA data?
The top bidder in the DNA testing firm's bankruptcy auction, Regeneron vows to prioritize the privacy, security, and ethical use of customer data.
23andMe was once worth $6 billion. What's left of the DNA testing startup is being bought for $256 million.
Regeneron is buying the assets of 23andMe, which filed for Chapter 11 bankruptcy in March after facing a series of hurdles including a data breach.
Genetic data will be safeguarded with 23andMe sale, drugmaker vows
The pharmaceutical giant plans to continue offering 23andMe’s DNA testing service and pledged to adopt its privacy practices to protect customer data.
Feedback